Objective To investigate changes in the level of serum CEA,Ferritin and plasma D-D of the lung cancer patients suffering before and after the chemotherapy,and evaluate its application value in judging the curative effect of chemotherapy on the lung cancer patients.Methods Chose 120 lung cancer patients diagnosed from September 2011 to September 2014, and determined the curative effect in accordance with the standard for evaluating the curative effect of solid tumors set down by WHO.Chose another group of 120 healthy physical examinees as its control group.Tested the contents of serum CEA, Ferritin and plasma D-D of both groups respectively and analyzed the rules of change in the results of the patients before and after chemotherapy and in different chemotherapeutic effect stages.Results The contents of serum CEA,Ferritin and plas-ma D-D of the lung cancer patients were obviously higher than those of such patients after chemotherapy and those of the control group,and the difference was of statistical significance (t=4.123~14.224,P <0.05).The contents of serum CEA, Ferritin and plasma D-D of the patient at complete remission (CR)stage were lower than those at partial remission (PR) stage,stable disease (SD)stage and progress disease (PD)stage,and the difference was of statistical significance (t=4.230~12.336,P <0.05).Conclusion The test on the serum CEA,Ferritin and plasma D-D of the lung cancer patients before and after chemotherapy is of certain clinical value and the change in their content levels can be taken as a reference index for the chemotherapeutic effect of lung cancer patients.

Objective To investigate application value of changes in serum neuron-specific enolase (NSE)in early diagnosis of diabetic peripheral neuropathy (DPN).Methods 160 cases of diabetes were recruited from January 2013 to December 2014, 120 of which were combined with DPN according to the 2009 “DPN Diagnostic & Treatment Guidelines”(the DPN group), and the other 40 were not (the DM group).Patients were further stratified into mild,moderate,and severe DPNs according to the Toronto Clinical Scoring System (TCSS).Another 160 healthy subjects were recruited as control.Serum NSE level was determined by chemiluminescence immunoassay,and was compared among the DPN group,the DM group,and the con-trol group.Serum NSE levels were also compared among DPN patients with different serum glucose levels and different TC-SS grading.Results Serum NSE levels (μg/L)of the DPN group,DM group,and control group were 23.5±3.0,12.4±2.3 and 11.3±1.6 respectively,and the difference between DPN and the other two groups was significant (t=12.312,14.523, P <0.05).DPN patients with serum glucose levels of 3.9~6.1,6.1 ~8.0,and ≥8.0 mmol/L had NSE levels of 22.1 ± 1.6,23.6±1.2 and 25.0±1.5 respectively,and the difference was significant (t =4.021 ~ 7.534,P <0.05 for all).DPN patients with mild,moderate,and severe DPN had NSE levels of 21.6±1.1,23.1±1.5,25.2±1.3,and the difference was significant (t=3.320~5.526,P <0.05 for all).NSE level was positively correlated with TCSS score (r=0.572,P <0.05). Conclusion Serum NSE level is closely correlated with DPN,and can be used as a key indicator for early diagnosis of DPN.

Objective To assess the prognostic value of HER2 (human epidermal growth factor receptor-2) somatic mutations S310F and V777L in breast cancer patients.Methods HER2 somatic mutations S310F and V777L was screened in 338 consecutive patients with operable primary breast cancer using direct Sanger sequencing analysis.Results A total of 12 carriers of HER2 gene S310F and V777L mutations were found,10 were HER2-negative and 2 were HER2-positive.The median follow-up was 43 months (range from 1 to 61 months).4 were found with local or distant metastasis,and all were HER2-negative patients.Survival analysis found significantly lower survival rates in patients with S3 10F and V777L mutations than in non-carriers (RFS,unadjusted hazard ratio [HR]:5.89,95％ confidence interval [CI]:1.96-17.71,P ＜ 0.001;DRFS,unadjusted HR:5.53,95％ CI:1.56-19.55,P =0.003) and this difference was more manifest in the HER2-negative patients (RFS,unadjusted HR:8.93,95％ CI:2.79-28.62,P ＜ 0.001;DRFS,unadjusted HR:9.89,95％ CI:2.54-38.49,P ＜ 0.001).HER2 somatic mutations S310F and V777L are independent predictors of poor prognosis in breast cancer.Conclusion The prognosis of breast cancer patients carrying HER2 somatic mutations S310F and V777L is significantly worse than that of non-carriers,especially in HER2-negative patients.

Objective To investigate the clinical pathological characteristics and prognosis of primitive neuroectodermal tumor (PNET) of breast.Methods Patients with breast PNET were retrieved from CNKI,Pubmed,Europe PMC and other databases from Jan.1980 to Dec.2016.The clinical data of one patient with breast PNET in our hospital were analyzed retrospectively.Results 18 cases had painless,rapid growth mass as the main clinical features.The pathological morphology showed small round cell tumors,PAS staining positive.Immunohistochemistry CD99 and Fli-1 characteristic expression were the main indexes for the diagnosis of breast PNET.The positive expression of Vimentin,NSE,Syn and negative expression of CK,EMA,Desmin,CgA,LCA,S-100 also played an important role in the diagnosis of breast PNET.The positive expression of genetic marker EWSRI was the golden standard for diagnosis of breast PNET.The size of the tumor,surgical treatment,lymph node metastasis,distant metastasis and chemotherapy were the important factors that affect the prognosis of the PNET.The survival rates of 1 and 3 years were 71.4％ and 33.3％ respectively.Conclusions Breast PNET is a rare tumor with poor prognosis,and its diagnosis is highly dependent on pathology.Surgery can significantly improve the prognosis of the patients.Surgery should be the main treatment,combined with radiotherapy and chemotherapy.The current study does not show evidence of effectiveness in terms of endocrine or targeted drug therapy for breast PNET patients.